Takeda says cancer drug Alunbrig shows longer benefit vs. crizotinib
Japan's biggest drugmaker, Takeda Pharmaceutical Co Ltd, said long-term data show better outcomes for its Alunbrig drug in certain lung cancer patients compared to an existing treatment.
No comments:
Post a Comment